Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma
出版年份 2016 全文链接
标题
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma
作者
关键词
-
出版物
AMERICAN JOURNAL OF HEMATOLOGY
Volume 91, Issue 9, Pages 923-930
出版商
Wiley
发表日期
2016-06-17
DOI
10.1002/ajh.24451
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study
- (2016) S. Dubois et al. CLINICAL CANCER RESEARCH
- Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling
- (2015) Ji Yuan et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing
- (2015) Jasper E. Neggers et al. CHEMISTRY & BIOLOGY
- CRM1 as a new therapeutic target for non-Hodgkin lymphoma
- (2015) Xiaohong Han et al. LEUKEMIA RESEARCH
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma
- (2015) Linka Xie et al. Oncotarget
- Rgb: a scriptable genome browser for R
- (2014) Sylvain Mareschal et al. BIOINFORMATICS
- Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL
- (2014) J. Bond et al. BLOOD
- Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?
- (2014) Kieron Dunleavy et al. BLOOD
- Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
- (2014) J. Reichel et al. BLOOD
- Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma
- (2014) Mariko Yoshimura et al. CANCER SCIENCE
- Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling
- (2014) Irfana Muqbil et al. CURRENT PHARMACEUTICAL DESIGN
- Nucleo-cytoplasmic transport as a therapeutic target of cancer
- (2014) Giovanni Luca Gravina et al. Journal of Hematology & Oncology
- A general framework for estimating the relative pathogenicity of human genetic variants
- (2014) Martin Kircher et al. NATURE GENETICS
- Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma
- (2014) Jay Gunawardana et al. NATURE GENETICS
- Genomic and molecular characterization of esophageal squamous cell carcinoma
- (2014) De-Chen Lin et al. NATURE GENETICS
- KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
- (2013) Julia Etchin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting the Nuclear Transport Machinery by Rational Drug Design
- (2013) Lei Mao et al. CURRENT PHARMACEUTICAL DESIGN
- Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
- (2013) Richard Delarue et al. LANCET ONCOLOGY
- SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
- (2013) S Jeromin et al. LEUKEMIA
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)
- (2012) N. Ketterer et al. ANNALS OF ONCOLOGY
- Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
- (2012) R. Lapalombella et al. BLOOD
- Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large B-Cell Lymphoma?
- (2012) Kieron Dunleavy et al. Current Hematologic Malignancy Reports
- The molecular pathogenesis of primary mediastinal large B-cell lymphoma
- (2011) C. Steidl et al. BLOOD
- Jetset: selecting the optimal microarray probe set to represent a gene
- (2011) Qiyuan Li et al. BMC BIOINFORMATICS
- Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA
- (2011) O. Fitoussi et al. HAEMATOLOGICA
- Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
- (2011) Christian Récher et al. LANCET
- Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial
- (2011) Frédéric Peyrade et al. LANCET ONCOLOGY
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma
- (2009) O. Ritz et al. BLOOD
- Structural basis for leucine-rich nuclear export signal recognition by CRM1
- (2009) Xiuhua Dong et al. NATURE
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search